Cargando…

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

Detalles Bibliográficos
Autores principales:	Roboz, Gail J., Döhner, Hartmut, Pocock, Christopher, Dombret, Hervé, Ravandi, Farhad, Jang, Jun Ho, Selleslag, Dominik, Mayer, Jiří, Martens, Uwe M., Liesveld, Jane, Bernal, Teresa, Wang, Ming Chung, Yu, Peiwen, Shi, Ling, Guo, Shien, La Torre, Ignazia, Skikne, Barry, Dong, Qian, Braverman, Julia, Nehme, Salem Abi, Beach, C. L., Wei, Andrew H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634169/ https://www.ncbi.nlm.nih.gov/pubmed/34551506 http://dx.doi.org/10.3324/haematol.2021.279174

Ejemplares similares

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
por: Döhner, Hartmut, et al.
Publicado: (2018)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
por: Pleyer, Lisa, et al.
Publicado: (2017)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
por: Seymour, John F., et al.
Publicado: (2017)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
por: Zeidan, Amer M., et al.
Publicado: (2022)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
por: Babiker, Hani M., et al.
Publicado: (2020)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
por: Almeida, António, et al.
Publicado: (2016)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA
por: Fleming, Shaun, et al.
Publicado: (2023)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
por: Savona, Michael R., et al.
Publicado: (2018)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Daver, Naval, et al.
Publicado: (2023)

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
por: Leisch, Michael, et al.
Publicado: (2020)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
por: Liang, Guanghao, et al.
Publicado: (2023)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
por: Lehner, Kara M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ek4pvgukd8so79phvmhjmvh18f